Related Experiment Video
Updated: Oct 5, 2026

Monitoring Neutrophil Elastase and Cathepsin G Activity in Human Sputum Samples
Published on: May 21, 2021
Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor
C C Taggart1, G J Lowe, C M Greene
1Pulmonary Research Division, Department of Medicine, The Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Abstract:
A number of serine proteases, matrix metalloproteases, and cysteine proteases were evaluated for their ability to cleave and inactivate the antiprotease, secretory leucoprotease inhibitor (SLPI). None of the serine proteases or the matrix metalloproteases examined cleaved the SLPI protein. However, incubation with cathepsins B, L, and S resulted in the cleavage and inactivation of SLPI. All three cathepsins initially cleaved SLPI between residues Thr(67) and Tyr(68). The proteolytic cleavage of SLPI by all three cathepsins resulted in the loss of the active site of SLPI and the inactivation of SLPI anti-neutrophil elastase capacity. Cleavage and inactivation were catalytic with respect to the cathepsins, so that the majority of a 400-fold excess of SLPI was inactivated within 15 min by cathepsins L and S. Analysis of epithelial lining fluid samples from individuals with emphysema indicated the presence of cleaved SLPI in these samples whereas only intact SLPI was observed in control epithelial lining fluid samples. Active cathepsin L was shown to be present in emphysema epithelial lining fluid and inhibition of this protease prevented the cleavage of recombinant SLPI added to emphysema epithelial lining fluid. Taken together with previous data that demonstrates that cathepsin L inactivates alpha(1)-antitrypsin, these findings indicate the involvement of cathepsins in the diminution of the lung antiprotease screen possibly leading to lung destruction in emphysema.
Insights
Cathepsins B, L, and S cleave and inactivate secretory leucoprotease inhibitor (SLPI), a key lung antiprotease. This cleavage was observed in emphysema patients, suggesting cathepsins contribute to lung destruction.
Area of Science:
- Biochemistry
- Protease Inhibitor Function
- Pulmonary Medicine
Background:
- Secretory leucoprotease inhibitor (SLPI) is a crucial antiprotease in the lung.
- Dysregulation of antiprotease activity is implicated in lung diseases like emphysema.
Purpose of the Study:
- To investigate the susceptibility of SLPI to various proteases.
- To determine the role of cathepsins in SLPI inactivation and their relevance in emphysema.
Main Methods:
- In vitro assays using purified proteases and SLPI.
- Analysis of epithelial lining fluid from emphysema patients and controls.
- Protease inhibition experiments.
Main Results:
- Cathepsins B, L, and S, but not serine or matrix metalloproteases, cleaved and inactivated SLPI.
- Cleavage occurred between Thr(67) and Tyr(68), abolishing SLPI's anti-neutrophil elastase activity.
- Cleaved SLPI and active cathepsin L were detected in emphysema patient samples.
- Inhibition of cathepsin L prevented SLPI cleavage in emphysema fluid.
Conclusions:
- Cathepsins actively degrade SLPI in the lung.
- Cathepsin-mediated inactivation of SLPI contributes to the diminished lung antiprotease screen in emphysema.
- Targeting cathepsins may offer a therapeutic strategy for emphysema.
Related Concept Videos
Caspases
Acute Pancreatitis II: Pathophysiology
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

